ClinicalTrials.gg
Active, not recruitingNCT06634316Updated May 6, 2025

Sarcopenia in Patients With Heart Failure

An interventional study of Mediterranean diet and Hypercaloric, hyperproteic oral nutritional supplement in Sarcopenia, sponsored by Maimónides Biomedical Research Institute of Córdoba. Active, not recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-06.

Sponsored by Maimónides Biomedical Research Institute of Córdoba · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 99 studies in Sarcopenia with a site in Spain — 33 open to participants now, 40 under way, none of them phase 3. Sarcopenia · Spain.

Planned enrollment
42nd of 77
60 · median 72
Started
2024
with 13 others
No phase
70 of 99
26 open now
Primary completion
2026-12
later than 20 of 39 live
Registered
54th of 99
by date
Lead sponsor
4 of 99
Maimónides Biomedical Research Institute of Córdoba

Among the 99 studies in Sarcopenia with a site in Spain, this one is the 42nd largest by planned enrollment of the 77 interventional ones that give a count, is one of 14 that started in 2024, is one of 70 with no phase, reaches primary completion later than 20 of the 39 other live ones, and was the 54th registered.

Sarcopenia

1,334 studies on the registry are indexed under Sarcopenia; 418 are open to participants now.

Browse Sarcopenia studies →

Open to participants now

33 of the 99 studies in Sarcopenia with a site in Spain are open now. Recruiting first, the newest first:

28 more — sign in →

All 33 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 246 Sarcopenia studies recruiting now, 155 (63%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 62 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 99 studies in Sarcopenia with a site in Spain, or all of them as a file.
02

Study summary

Sarcopenia is a frequent complication in patients with cancer and chronic diseases, it is characterized by decreased muscle strength and fatigue due to reduced skeletal muscle mass, which is accompanied by atrophy and decreased quality of muscle tissue. In all cases, it negatively impacts treatment tolerance, clinical outcomes and survival, in consequence, quality of life of these patients decreases while morbidity, mortality and costs increase. In this context, appropriate nutritional screening and early nutrition support are extremely recommended, to this aim, in some cases, oral nutritional supplements (ONS) are necessary; ONS could have a standard formula or be enriched with specific nutrients. There is a lack of evidence for supporting its use or the use of protein modules in other clinical conditions including patients with heart failure

03

Conditions studied

  • Sarcopenia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with a previous admission due to HF in the previous 12 months
  • Moderate or severe
  • Both sexs
  • Age >18 years old.

Exclusion criteria

Exclusion Criteria:

  • \<15 ml/min
  • End-stage liver disease.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Mediterranean diet

    Mediterranean diet and physical exercise

    Other: Mediterranean diet · Combination Product: Vitamin D supplementation · Combination Product: Physical exercise

  • Experimental
    Standard hypercaloric hyperproteic Oral supplement

    Standard hypercaloric hyperproteic oral supplement plus Mediterranean diet and physical exercise

    Other: Mediterranean diet · Dietary Supplement: Hypercaloric, hyperproteic oral nutritional supplement · Combination Product: Vitamin D supplementation · Combination Product: Physical exercise

  • Experimental
    Protein module

    Protein module (10g/day) plus Mediterranean diet and physical exercise

    Other: Mediterranean diet · Dietary Supplement: Protein module · Combination Product: Vitamin D supplementation · Combination Product: Physical exercise

Interventions

  • OtherMediterranean diet

    Mediterranean diet recommendations and daily physical exercise

  • Dietary supplementHypercaloric, hyperproteic oral nutritional supplement

    Hypercaloric, hyperproteic oral supplement combined with Mediterranean diet recommendations (2 per day) and daily physical exercise

  • Dietary supplementProtein module

    Protein module (10g/day) combined with Mediterranean diet recommendations and daily physical exercise

  • Combination productVitamin DStudies of Vitamin DVitamin D pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Calcifediol supplement administered orally in order to reach sufficiency levels (30 ng/ml)

  • Combination productPhysical exercise

    Physical exercise adapted to patients with heart failure (Cardiac rehabilitation)

06

What researchers measure

Primary outcomes

  1. Muscle mass

    Changes in muscle mass

    Time frame: 6 months

  2. Functionality

    Changes in functionality determined by the up and go test

    Time frame: 6 months

Secondary outcomes

  1. Albumin

    Changes in serum albumin levels (g/dl)

    Time frame: 6 months

  2. C-RP

    Changes in serum C-RP (g/dl)

    Time frame: 6 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Dec 2026, 25 months after the start.

Of 497 non-industry interventional studies with no phase under Sarcopenia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 34. This study's planned 25 months is above that.

Counting every sponsor, half of 509 studies reached it within 18 months; a quarter within 8 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2023
First posted
Oct 9, 2024
StartActual
Nov 15, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
May 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06634316
Lead sponsor
Maimónides Biomedical Research Institute of Córdoba
Responsible party
Sponsor
First posted
Oct 9, 2024
Start date
Nov 15, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
May 6, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion